The Clinical Value of Combined Detection of Serum Tumor Markers CEA and CA19-9 in digestive system malignancies Diagnosis

Zhao Lei,Wu Xiangling
DOI: https://doi.org/10.3969/j.issn.1672-2566.2009.05.025
2009-01-01
Abstract:Objective To evaluate and discuss the clinical value of single and combined detection of serum tumor makers with CEA and CA19-9 in several diagnosed malignancies in digestive system. Methods The single and combined detecting results of serum with CEA, CA199 in 439 patients with digestive tract diseases were retrospectively analyzed, the pathological diagnosis is the standard one, there are 272 benign and 167 malignant tumors among them. Results CEA and CA19-9 combined detection makes the sensitivity of diagnosis of malignant tumors increasing, especially for the diagnosis of gallbladder cholangiocarcinoma, pancreatic cancer, the sensitivity has raised up from 41.7%, 83.3% (gallbladder cholangiocarcinoma), 55.6%, 77.8% (pancreatic cancer), by the single dictation, to 91.7% (gallbladder cholangiocarcinoma), 83.3% (pancreatic cancer); however, the combined detection makes the specificity decreased. The positive likelihood ratio by the combined detection is lower than that of the highest single item; and the negative likelihood ratio is lower than that of the single one, but the positive likelihood ratio by the combined detection with esophageal cancer has significantly increased. Conclusions Tumor markers CEA and CA19-9 are of an important value as a diagnostic test for malignant tumors in digestive tract, especially for the gallbladder bile duct and pancreatic cancer. The combined detection greatly improves the sensitivity of the gallbladder bile duct and pancreatic cancer, and can reduce the rate of missed diagnosis of gastrointestinal cancer.
What problem does this paper attempt to address?